title: Hemodynamic and biochemical alterations in dogs with lymphoma after induction of chemotherapy.
abstract: BACKGROUND
  Doxorubicin is a common antineoplastic agent with dose-dependent cardiotoxic adverse effects, and pre-existing myocardial dysfunction is a contraindication to its use.
  
  
  OBJECTIVE
  To systematically define the hemodynamic and biochemical alterations in dogs undergoing chemotherapy for newly diagnosed lymphoma and assess the reversibility of these alterations with fluid administration.
  
  
  METHODS
  Twenty-one client-owned dogs with newly diagnosed lymphoma were evaluated 1 week after induction of chemotherapy. Underlying degenerative valve disease was exclusionary. Eighteen healthy age- and weight-matched dogs were used as controls.
  
  
  METHODS
  Physical examination, blood pressure by Doppler, echocardiography, and biochemical evaluation (routine serum biochemistry, plasma renin activity and aldosterone concentrations, plasma and urine osmolalities, and urine electrolyte concentrations) were measured in dogs with lymphoma and compared to controls. Dogs with lymphoma received crystalloids IV at 6 mL/kg/h for 24 hours. All variables were reassessed at 4 and 24 hours. Deuterium oxide dilution and bromide dilution were used to determine total body water and extracellular water space, respectively.
  
  
  RESULTS
  Baseline echocardiograms showed significantly smaller chamber dimensions in dogs with lymphoma compared to controls. These changes were reversed by fluid administration. Systolic blood pressure and urine sodium concentration were significantly increased, and bromide dilution space, PCV, urine specific gravity, and urine potassium concentration were significantly decreased compared to controls.
  
  
  CONCLUSIONS
  Echocardiographic and biochemical abnormalities in dogs with lymphoma appear consistent with volume depletion, and may be the result of systemic hypertension and subsequent pressure natriuresis.
authors.affiliation: Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO.
authors.forename: D M
authors.initials: DM
authors.lastname: Fine
authors.forename: K
authors.initials: K
authors.lastname: Selting
authors.forename: R C
authors.initials: RC
authors.lastname: Backus
authors.forename: N F
authors.initials: NF
authors.lastname: Rossi
authors.forename: M W
authors.initials: MW
authors.lastname: Harmon
authors.forename: H E
authors.initials: HE
authors.lastname: Durham
authors.forename: A W
authors.initials: AW
authors.lastname: Spier
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000097:blood; D004283:Dog Diseases / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004285:Dogs; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004452:Echocardiography / Q000662:veterinary; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D008223:Lymphoma / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology / Q000662:veterinary*; D011188:Potassium / Q000652:urine; D012964:Sodium / Q000652:urine
chemical_list: D000903:Antibiotics, Antineoplastic; D001786:Blood Glucose; D004317:Doxorubicin; D012964:Sodium; D003404:Creatinine; D011188:Potassium
keywords: Doxorubicin; Extracellular volume depletion; Lymphoma; Prednisone; Systemic hypertension